Since then, few studies have estimated the TTB for statins therapy,14 blood pressure treatment,15 and bisphosphonate therapy.16 Unlike these treatments with a long delay between initiation of treatment and clinical benefit (eg, 1 year after antihypertensive treatment), SGLT2 inhibitors may implicate early immediate clinical outcomes due to their early physiologic changes among patients with HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.